JPH0258920B2 - - Google Patents

Info

Publication number
JPH0258920B2
JPH0258920B2 JP56503268A JP50326881A JPH0258920B2 JP H0258920 B2 JPH0258920 B2 JP H0258920B2 JP 56503268 A JP56503268 A JP 56503268A JP 50326881 A JP50326881 A JP 50326881A JP H0258920 B2 JPH0258920 B2 JP H0258920B2
Authority
JP
Japan
Prior art keywords
thrombin
heparin
antithrombin
nacl
buffer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP56503268A
Other languages
English (en)
Japanese (ja)
Other versions
JPS57501510A (enExample
Inventor
Herumuuto Riru
Yurugen Shurenku
Peetaa Undaauaruto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Roche Diagnostics GmbH
Original Assignee
Boehringer Mannheim GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19803038163 external-priority patent/DE3038163A1/de
Application filed by Boehringer Mannheim GmbH filed Critical Boehringer Mannheim GmbH
Publication of JPS57501510A publication Critical patent/JPS57501510A/ja
Publication of JPH0258920B2 publication Critical patent/JPH0258920B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/56—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving blood clotting factors, e.g. involving thrombin, thromboplastin, fibrinogen
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
    • G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • G01N2333/811—Serine protease (E.C. 3.4.21) inhibitors
    • G01N2333/8121—Serpins
    • G01N2333/8128—Antithrombin III
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/974—Thrombin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/10—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • G01N2400/38—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence, e.g. gluco- or galactomannans, Konjac gum, Locust bean gum or Guar gum
    • G01N2400/40—Glycosaminoglycans, i.e. GAG or mucopolysaccharides, e.g. chondroitin sulfate, dermatan sulfate, hyaluronic acid, heparin, heparan sulfate, and related sulfated polysaccharides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP56503268A 1980-10-09 1981-10-08 Expired - Lifetime JPH0258920B2 (enExample)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19803038163 DE3038163A1 (de) 1980-10-09 1980-10-09 Thrombininhibitor, seine herstellung und verwendung
DE3050268 1981-08-04

Publications (2)

Publication Number Publication Date
JPS57501510A JPS57501510A (enExample) 1982-08-26
JPH0258920B2 true JPH0258920B2 (enExample) 1990-12-11

Family

ID=25788386

Family Applications (1)

Application Number Title Priority Date Filing Date
JP56503268A Expired - Lifetime JPH0258920B2 (enExample) 1980-10-09 1981-10-08

Country Status (6)

Country Link
US (1) US4496653A (enExample)
EP (1) EP0049877B1 (enExample)
JP (1) JPH0258920B2 (enExample)
DE (1) DE3163764D1 (enExample)
DK (1) DK160511C (enExample)
WO (1) WO1982001377A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3407280A1 (de) * 1984-02-28 1985-09-19 Gödecke AG, 1000 Berlin Testsatz zur bestimmung der aktivierten partiellen thromboplastinzeit (ptt) mit erhoehter heparinempfindlichkeit
DE3512909A1 (de) * 1985-04-11 1986-10-23 Behringwerke Ag, 3550 Marburg Verfahren zur bestimmung von plasminogenaktivatoren (pa)
NL8902406A (nl) * 1989-09-27 1991-04-16 Hendrik Coenraad Hemker Prof D Werkwijze voor het bepalen van de endogene trombinepotentiaal van plasma, en bloed alsmede een bij deze werkwijze te gebruiken kit.
US5595735A (en) * 1990-05-23 1997-01-21 Johnson & Johnson Medical, Inc. Hemostatic thrombin paste composition
EP0509086B1 (en) * 1990-11-05 1995-04-12 Dade Produktions AG A method to determine the concentration of anticoagulants
DE4203980A1 (de) * 1992-02-11 1993-08-12 Max Planck Gesellschaft Verfahren zur bestimmung von hirudin und synthetischen thrombininhibitoren
AT397391B (de) * 1992-05-15 1994-03-25 Immuno Ag Verwendung von prothrombinfragmenten
WO1993025220A1 (en) * 1992-06-05 1993-12-23 Reid Thomas J Iii Test for quantitative thrombin time
US5476771A (en) * 1993-02-22 1995-12-19 The United States Of America As Represented By The Secretary Of The Army Test for quantitative thrombin time
US5308755A (en) * 1992-06-08 1994-05-03 Research Corporation Technologies, Inc. Method for measuring heparin
US5985582A (en) * 1997-12-09 1999-11-16 Sigma-Aldrich Co. Thrombin-based assay for antithrombin III
WO2016049545A1 (en) 2014-09-26 2016-03-31 Abbott Point Of Care Inc. Single channel cartridge device for coagulation assays in fluid samples
US10048281B2 (en) 2014-09-26 2018-08-14 Abbott Point Of Care Inc. Cartridge device with segmented fluidics for assaying coagulation in fluid samples
CN106999932A (zh) 2014-09-26 2017-08-01 雅培医护站股份有限公司 用于流体样本中的凝结测定的具有流体结的盒设备
EP3198281B1 (en) 2014-09-26 2023-01-25 Abbott Point Of Care, Inc. Ellagic acid formulations for use in coagulation assays
WO2016049506A1 (en) 2014-09-26 2016-03-31 Abbott Point Of Care Inc. Sensors for assaying coagulation in fluid samples
EP3198272B1 (en) 2014-09-26 2022-04-06 Abbott Point Of Care, Inc. Cartridge device identification for coagulation assays in fluid samples
US10247741B2 (en) 2014-09-26 2019-04-02 Abbott Point Of Care Inc. Microfabricated device with micro-environment sensors for assaying coagulation in fluid samples

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH622286A5 (enExample) * 1975-06-23 1981-03-31 Pentapharm Ag
SE419871B (sv) * 1975-12-01 1981-08-31 Pharmacia Ab Sett att bestemma aktiviteten hos faktor xa-inhibitor i blod
DE2601372C3 (de) * 1976-01-15 1980-03-27 Behringwerke Ag, 3550 Marburg Verfahren zur Bestimmung von Antithrombin III
DE2812943C3 (de) * 1978-03-23 1981-05-14 Boehringer Mannheim Gmbh, 6800 Mannheim Verfahren und Reagens zur Bestimmung der biologischen Aktivität von Heparin im Plasma
US4216142A (en) * 1978-12-18 1980-08-05 Abbott Laboratories Chromogenic substrates for the proteolytic enzymes
CA1136620A (en) * 1979-01-08 1982-11-30 Ulf P.F. Lindahl Heparin fragments having selective anticoagulation activity
DE3061860D1 (en) * 1979-04-24 1983-03-17 Marcel Jozefonvicz Process for the determination of proteases and antiproteases
CA1171375A (en) * 1980-09-15 1984-07-24 Ulf P.F. Lindahl Oligosaccharides having selective anticoagulation activity

Also Published As

Publication number Publication date
DE3163764D1 (en) 1984-06-28
WO1982001377A1 (en) 1982-04-29
DK237282A (da) 1982-05-26
DK160511C (da) 1991-09-30
EP0049877A1 (de) 1982-04-21
DK160511B (da) 1991-03-18
US4496653A (en) 1985-01-29
JPS57501510A (enExample) 1982-08-26
EP0049877B1 (de) 1984-05-23

Similar Documents

Publication Publication Date Title
JPH0258920B2 (enExample)
Harpel Alpha2-plasmin inhibitor and alpha2-macroglobulin-plasmin complexes in plasma. Quantitation by an enzyme-linked differential antibody immunosorbent assay.
Hogg et al. Fibrin monomer protects thrombin from inactivation by heparin-antithrombin III: implications for heparin efficacy.
Boisclair et al. Thrombin production, inactivation and expression during open heart surgery measured by assays for activation fragments including a new ELISA for prothrombin fragment F1+ 2
Soria et al. A new type of congenital dysfibrinogenaemia with defective fibrin lysis—Dusard syndrome: possible relation to thrombosis
Pixley et al. Effect of heparin on the inactivation rate of human activated factor XII by antithrombin III
Wiman [32] Human α2-antiplasmin
US5702912A (en) Method to determine the concentration of anticoagulants
Tans et al. Autoactivation of human plasma prekallikrein.
Abildgaard et al. A simple amidolytic method for the determination of functionally active antithrombin III
Espana et al. Determination of functional and antigenic protein C inhibitor and its complexes with activated protein C in plasma by ELISA's
Gabazza et al. Protein C activation in NIDDM patients
Pixley et al. Effect of negatively charged activating compounds on inactivation of factor XIIa by Cl inhibitor
JPH0476629B2 (enExample)
Abildgaard Inhibition of the thrombin-fibrinogen reaction by antithrombin III, studied by N-terminal analysis
JPH11235197A (ja) アンチトロンビンｉｉｉの測定方法
Pixley et al. Effect of heparin on the activation of factor XII and the contact system in plasma
JP2004075680A (ja) 止血補助因子としてｒｎａを含む医薬製剤
Ofosu et al. Inhibition of the amplification reactions of blood coagulation by site-specific inhibitors of α-thrombin
Aiach et al. Adaptation of synthetic peptide substrate-based assays on a discrete analyzer
Matsuda et al. Selective determination of α2-plasmin inhibitor activity in plasma using chromogenic substrate
Charlton et al. XR5118, a novel modulator of plasminogen activator inhibitor-1 (PAI-1), increases endogenous tPA activity in the rat
JP3157844B2 (ja) ヘパリン含有量の測定方法
Abildgaard Inhibition of the thrombin-fibrinogen reaction by α2-macroglobulin, studied by N-terminal analysis
Wu et al. Activated thrombin-activatable fibrinolysis inhibitor attenuates spontaneous fibrinolysis of batroxobin-induced fibrin deposition in rat lungs